Pancreatic Cancer Research

ResearcherKanazawa UniversityActive in the last 2 years

Takeo Shimasaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-5490-8271; OpenAlex author ID A5072908231. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 8

  1. Prognostic significance of fibroblast senescence and senescence-associated secretory phenotype factor expression in the tumor microenvironment of pancreatic du… Co-author DOI 10.3892/or.2025.9031↗
  2. Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer. Co-author DOI 10.20517/cdr.2023.84↗
  3. Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. First author DOI 10.1371/journal.pone.0055289↗
  4. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. Co-author DOI 10.1007/s00535-011-0484-9↗
  5. Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro. Co-author DOI 10.3892/or.2012.2020↗
  6. Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. Co-author DOI 10.4103/1477-3163.100866↗
  7. Human SMG-1 is involved in gemcitabine-induced primary microRNA-155/BIC up-regulation in human pancreatic cancer PANC-1 cells. Co-author DOI 10.1097/mpa.0b013e3181e89f74↗
  8. Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: implications for new therapeutic strategies. First author DOI 10.3390/cancers3010446↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tomoharu Miyashita · 2 shared papers, 2024–2026 · strength 0.56
  2. Toshinari Minamoto Md · 5 shared papers, 2011–2024 · strength 0.37
  3. Isamu Makino · 1 shared paper, 2026 · strength 0.32
  4. Shintaro Yagi · 1 shared paper, 2026 · strength 0.32
  5. Yuto Kitano · 1 shared paper, 2026 · strength 0.32
  6. Masahiro Uehara · 1 shared paper, 2024 · strength 0.24
  7. Yoshiharu Motoo · 6 shared papers, 2011–2013 · strength 0.19
  8. Ayako Kitano · 3 shared papers, 2012–2013 · strength 0.10
  9. Naohisa Tomosugi · 2 shared papers, 2012 · strength 0.06
  10. Takanobu Takata · 2 shared papers, 2012 · strength 0.06
  11. Yoshimichi Sai · 1 shared paper, 2013 · strength 0.03
  12. Qisheng Xia · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.